All News
The 2025 Rheumatology Year in Review
The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines and practices that will impact patient care for rheumatic diseases.
Read Article
Advanced Practitioner Biologic Prescriptions for Psoriasis
Advanced practice clinicians (APCs; nurse practitioners and physician assistants) deliver a large share of US dermatologic care, accounting for 37% of clinicians and 27% of dermatology visits by 2020. A current JAMA Dermatology reports APC drug spending trends in dermatology, with a focus on specialty medications (eg, biologics).
Read Article
Spread of Psoriatic Disease from Skin to Joints
Approximately 20 to 30 percent of all people who suffer from psoriasis also develop painful inflammation in their joints over time. If left untreated, psoriatic arthritis can lead to permanent damage to bones and joints.
Read Article
Antirheumatic drug use with rheumatoid arthritis pregnancies
A nationwide Norwegian registry study of rheumatoid arthritis (RA) pregnancies showed that while medication use increased during pregnancy, many discontinued treatment during pregnancy, only to resumed it after childbirth.
Read Article
Nursing Shortage Could Worsen Due to Limited Student Loans
On 11/6, a DOE rule-making committee released a new proposed framework excluding nursing from the so-called "professional degree" category -- a plan which, if finalized, would limit nurses' access to certain student https://t.co/0zpznqgdb7
Dr. John Cush RheumNow ( View Tweet)
GC dose and tapering may influence serious infection risk in patients with GCA. Discover the key safety outcomes observed during a year of JAKi therapy in a Phase 3 trial. Sponsored by AbbVie Medical Affairs +Health Impact. https://t.co/1B5dj7KJJr https://t.co/aRMAdanFhb
Dr. John Cush RheumNow ( View Tweet)
Rheumatoid & Inflammation Testing
https://t.co/tEkJWGp7DK https://t.co/ZO4BV2mmhn
Links:
Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Sjogren's Beyond the Dryness
Caitlin Hill, FNP, and David Maniscalco, MD, Santa Rosa, CA present this QD Clinic: Sjogren's - Beyond the Dryness.
https://t.co/4VHRmBm7GC https://t.co/pQV8klTzZV
Dr. John Cush RheumNow ( View Tweet)
Diffuse Alveolar Hemorrhage in Rheumatic Disease
A retrospective, cross-sectional, single-center study of adult rheumatic disease patients with diffuse alveolar hemorrhage (DAH), demonstrates a high proportion have coexistent pulmonary infection and significant mortality risk. https://t.co/vpzF8Dnspr
Dr. John Cush RheumNow ( View Tweet)
Subcutaneous Anifrolumab in SLE
Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://t.co/3DWNEXaO2x
Dr. John Cush RheumNow ( View Tweet)
We're less than 30 days out from RheumNow Live and we want to see you there...in-person!
Why Attend In Person?
✔ Engage directly with faculty during live Q&A
✔ Network with peers who influence and lead in rheumatology
✔ Experience the energy, pace, and collaboration that https://t.co/tqSHYAEoOQ
Dr. John Cush RheumNow ( View Tweet)
Systematic review of cardiovascular death in systemic immune-mediated Dz (SIDs): 39 studies, 171,748 pts - SIDs assoc w/ signif. higher CV mortality (HR 1.26; 1.09-1.47; p = 0.002), especially for RA, SLE, GPA & females. 92% of CV deaths from acute coronary syndrome (ACS) https://t.co/ogLhqKMwON
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of Tramadol included 19 PBO-RCTs, 6506 pts, showing a very modest benefit on chronic pain (low certainty of evidence), but a doubling of risk for serious adverse events (OR 2.13); including nausea (NNH 7), dizziness (NNH 8), constipation (NNH 9), somnolence (NNH 13) https://t.co/0ZEIoy1gqC
Dr. John Cush RheumNow ( View Tweet)
Join us for STEP Talks at RheumNow Live! Big Ideas. Real Impact. No Filler!
https://t.co/vvLKFWatWe
Don’t miss these engaging discussions:
- Placebos in Rheumatology - Dr. Andreas Kerschbaumer
- Disease Modification in Osteoarthritis - Dr. Tuhina Neogi
- Helicobacter pylori https://t.co/lQRCLdMSh6
Links:
Dr. John Cush RheumNow ( View Tweet)
US Overdose Deaths have dropped in 2024 & 2025!. Overdose (opioids, heroin, fentanyl) deaths peaked at ~110,000 in 2022, fell a little in 2023, but plummeted (27%) to 80,000 in 2024. Reported deaths highes in the N. East & Atlantic states. https://t.co/P3mgrOzGhr https://t.co/eGOBhIx7ZB
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of recombinant zoster vaccine Rheumatic (RMD) pts on DMARDs (32% JAKi) (114) vs 65 normals. HZoster reactivation: no controls vs 1in RMD. 1 Dz flare requiried steroids. Minor AE (ISR, HA, myalgia) seen in 17.5% & 21.5% w/ 1st & 2nd dose. RZV is safe in RMD https://t.co/Hf7HaGOLXd
Dr. John Cush RheumNow ( View Tweet)
101 Meditteranean pregnant RA compared to 236 non-RA controls. HCQ & SSZ (45-73%) most used; biologics less (25%). RA had signif more adverse preg outcomes - LBW (OR 3), C-section (OR 2.55), fewer neonatal deaths (OR 0.38). RA had more miscarriages (20 v 1%) & fewer live births https://t.co/3nTdXEbBHI
Dr. John Cush RheumNow ( View Tweet)
In Dec 2025, the FDA qualified total hip bone mineral density (BMD) assessed by DXA as a validated surrogate endpoint for osteoporosis clinical trials. Previously OP trials required fracture endpoints as primary efficacy measures, necessitating large 2-5 yr studies https://t.co/q8a7QmoIXs
Dr. John Cush RheumNow ( View Tweet)
Subcutaneous Anifrolumab in SLE
Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://t.co/yrAirr2R2Y
Dr. John Cush RheumNow ( View Tweet)
Retrospective single center --103 EGPA pts finds 36 (35%) w/ cardiac involvement, having cardiac Sxs & biomarkers. Most common: pericarditis (77%), cardiomyopathy w/ CHF (55%), myocarditis (36%), cardiogenic shock (14%), cardiac arrest (6%), coronary v.asospasm (8%) https://t.co/JNdVNlVWvA
Dr. John Cush RheumNow ( View Tweet)
